AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9127568 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' views on hospitals making active efforts to improve health care and treatment skills
Number of subjects: 293
Study 9127568 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference to their own clinical data to improve health care and treatment skills
Number of subjects: 293
Study 1541798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (dl‐alpha‐tocopherol), 1200 IU/day, orally for 4 months
Number of subjects: 100
Study 1541798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1541798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (dl‐alpha‐tocopherol)
Number of subjects: 100
Study 3031154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine with oral thymoxamine (alpha‐noradrenergic antagonist)
Number of subjects: 0
Study 30509231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear avoidance beliefs about work
Number of subjects: 559
Study 30509231 — intervention group
Group type: COMPARATOR
Intervention: Fear avoidance beliefs about physical activity
Number of subjects: 559
Study 26827250 — intervention group
Group type: EXPERIMENTAL
Intervention: SHUTi (online insomnia program based on cognitive behavioural therapy for insomnia)
Number of subjects: 1149
Study 26827250 — intervention group
Group type: COMPARATOR
Intervention: HealthWatch (interactive, attention-matched, internet-based placebo control program)
Number of subjects: 1149
Study 23834300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1585
Study 23834300 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1585
Study 22773036 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69ST membrane (n = 75)
Number of subjects: 39
Study 22773036 — intervention group
Group type: COMPARATOR
Intervention: Original AN69 membrane (n = 76)
Number of subjects: 39
Study 22773036 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69ST membrane (n = 62)
Number of subjects: 39
Study 22773036 — intervention group
Group type: COMPARATOR
Intervention: Original AN69 membrane (n = 56)
Number of subjects: 39
Study 20163921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GPN) titrated to 2400mg/day
Number of subjects: 45
Study 18394157 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 41
Study 16238587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 30 microl/kg per dose, administered every 15 min
Number of subjects: 150
Study 16238587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus fluticasone 500 microg/dose at 15 and 30 min after first dose of salbutamol
Number of subjects: 150
Study 16238587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol/fluticasone 500 microg/dose, each combined dose administered every 15 min
Number of subjects: 150
Study 12723744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 8677
Study 12723744 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 3 g/day
Number of subjects: 8677
Study 12723744 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 3 g/day
Number of subjects: 8677
Study 10588560 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan (n = 79)
Number of subjects: 158
Study 10588560 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Whitacre (n = 79)
Number of subjects: 158
Study 8759664 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBDQ (Short Inflammatory Bowel Disease Questionnaire)
Number of subjects: 194
Study 1920177 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy with a nurse therapist
Number of subjects: 42
Study 1920177 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 42
Study 1920177 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy
Number of subjects: 42
Study 30909945 — intervention group
Group type: EXPERIMENTAL
Intervention: AA supplement for 15 days prior to the race
Number of subjects: 41
Study 30909945 — intervention group
Group type: COMPARATOR
Intervention: Non-AA group (no supplement)
Number of subjects: 41
Study 30909945 — intervention group
Group type: EXPERIMENTAL
Intervention: AA group
Number of subjects: 41
Study 27677411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1723
Study 27677411 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1723
Study 27677411 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus tirofiban
Number of subjects: 1723
Study 25776953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone increase
Number of subjects: 44
Study 23561287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diazepam solution (10mg)
Number of subjects: 24
Study 23561287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diazepam suspension (10mg)
Number of subjects: 24
Study 23561287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (5mg)
Number of subjects: 24
Study 22129158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 3035
Study 19879462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter guidance
Number of subjects: 425
Study 19879462 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment to guide therapy
Number of subjects: 425
Study 19879462 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in HRQOL by 1 month
Number of subjects: 425
Study 19879462 — intervention group
Group type: EXPERIMENTAL
Intervention: No improvement in HRQOL by 1 month
Number of subjects: 425
Study 17664404 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 788
Study 17664404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 16274603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O2 concentration during embryo culture
Number of subjects: 712
Study 16274603 — intervention group
Group type: COMPARATOR
Intervention: 20% O2 concentration during embryo culture
Number of subjects: 712
Study 12140498 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated emergency department-based strategy with low-molecular-weight heparin and early cardioversion to sinus rhythm
Number of subjects: 18
Study 12140498 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach of hospital admission
Number of subjects: 18
Study 12140498 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 10194770 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV myelitis in drug users (17%)
Number of subjects: 90
Study 10194770 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic infections
Number of subjects: 90
Study 10194770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphomas
Number of subjects: 90
Study 10194770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe vacuolar myelopathy
Number of subjects: 90
Study 10194770 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV proviral load
Number of subjects: 90
Study 7483087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (100 mg IV twice daily for four days, followed by 150 mg orally twice daily for five days)
Number of subjects: 24
Study 7483087 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 24
Study 7483087 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study 2106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion before and during CPB
Number of subjects: 0
Study 2106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion
Number of subjects: 0
Study 2106334 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 6117681 — intervention group
Group type: COMPARATOR
Intervention: Neither antibiotics nor myringotomy
Number of subjects: 171
Study 6117681 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy only
Number of subjects: 171
Study 6117681 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 171
Study 6117681 — intervention group
Group type: COMPARATOR
Intervention: Both antibiotics and myringotomy
Number of subjects: 171
Study 31808012 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 10
Study 31808012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31989162 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage condition
Number of subjects: 38
Study 31989162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 38
Study 31989162 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-regulation task
Number of subjects: 38
Study 31989162 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anger experiences
Number of subjects: 38
Study 27773351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-scan protocol
Number of subjects: 426
Study 25862215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperstown cocktail + oral LDX 70 mg
Number of subjects: 30
Study 25862215 — intervention group
Group type: COMPARATOR
Intervention: Cooperstown cocktail
Number of subjects: 30
Study 23541571 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pretreatment serum LDH level (109.0-245.0 U/L)
Number of subjects: 400
Study 23541571 — intervention group
Group type: COMPARATOR
Intervention: Elevated pretreatment serum LDH level (≥245.0 U/L)
Number of subjects: 400
Study 23541571 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal LDH (median point of 177.0 U/L)
Number of subjects: 400
Study 23541571 — intervention group
Group type: COMPARATOR
Intervention: LDH level 178.0-245.0 U/L
Number of subjects: 400
Study 21408060 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically enhanced website intervention
Number of subjects: 7935
Study 21408060 — intervention group
Group type: COMPARATOR
Intervention: Typical alcohol website providing information on potential harms of alcohol (Control)
Number of subjects: 7935
Study 19733606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg
Number of subjects: 80
Study 19733606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17109335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (rAd5 vector HIV-1 candidate vaccine) at dose levels of 10^9 (n=10), 10^10 (n=10), or 10^11 (n=10) particle units
Number of subjects: 30
Study 17109335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (rAd5 vector HIV-1 candidate vaccine)
Number of subjects: 30
Study 17109335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14718327 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care team consultations, advance care planning, psychosocial support, and family caregiver training.
Number of subjects: 90
Study 14718327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 90
Study 14718327 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care team consultations.
Number of subjects: 90
Study 11758237 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg every 12 hours (or 1g every 12 hours if necessary)
Number of subjects: 112
Study 11758237 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1g/1g every 12 hours if necessary)
Number of subjects: 112
Study 11758237 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 112
Study 11758237 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 112
Study 9398796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 14.8 +/- 0.86 mmol/liter)
Number of subjects: 11
Study 9398796 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 3.8 +/- 0.6 mmol/liter)
Number of subjects: 11
Study 10151019 — intervention group
Group type: EXPERIMENTAL
Intervention: 6Fr Novoste RCA catheters
Number of subjects: 100
Study 10151019 — intervention group
Group type: COMPARATOR
Intervention: 6Fr Judkins RCA catheters
Number of subjects: 100
Study 2959448 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate 150mg
Number of subjects: 1216
Study 2959448 — intervention group
Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate 100mg
Number of subjects: 1216
Study 2959448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of DMPA
Number of subjects: 1216
Study 29406180 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 4 mg
Number of subjects: 115
Study 29406180 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 8 mg
Number of subjects: 115
Study 29406180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. normal saline)
Number of subjects: 115
Study 27397662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid accumulation in the neck (ΔNC)
Number of subjects: 20
Study 27397662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid accumulation in the neck (ΔNFV)
Number of subjects: 20
Study 27397662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sleep neck circumference (NC)
Number of subjects: 20
Study 27397662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference (NC) and neck fluid volume (NFV)
Number of subjects: 20
Study 24067888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (100 mg, monthly i.v.)
Number of subjects: 60
Study 24067888 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg, standard therapy)
Number of subjects: 60
Study 22486380 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement (ERL)
Number of subjects: 28
Study 22486380 — intervention group
Group type: COMPARATOR
Intervention: Mechanical scaling and root planing (SRP)
Number of subjects: 28
Study 20831543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 or 30 mg daily) for 3 months
Number of subjects: 49
Study 20831543 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of pioglitazone after 3 months
Number of subjects: 49
Study 20831543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment in post-menopausal women
Number of subjects: 49
Study 18584464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Dependence Syndrome Scale (NDSS) Priority subscale
Number of subjects: 0
Study 18584464 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Inventory of Smoking Dependence Motives (WISDM) Tolerance subscale
Number of subjects: 0
Study 18584464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerstrom Test of Nicotine Dependence (FTND)
Number of subjects: 0
Study 18584464 — intervention group
Group type: EXPERIMENTAL
Intervention: WISDM subscales
Number of subjects: 0
Study 15671089 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 6 months (group A)
Number of subjects: 34
Study 15671089 — intervention group
Group type: EXPERIMENTAL
Intervention: GH deprivation for 6 months (group A)
Number of subjects: 34
Study 15671089 — intervention group
Group type: EXPERIMENTAL
Intervention: GH addition for 6 months (group B)
Number of subjects: 34
Study 15671089 — intervention group
Group type: COMPARATOR
Intervention: Control (no GH for 6 months, group B)
Number of subjects: 34
Study 15671089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IMT after 6 months (group A)
Number of subjects: 34
Study 15671089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IMT after 6 months (group B)
Number of subjects: 34
Study 12135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ARTS (135 mg; 352 micromol)
Number of subjects: 8
Study 12135281 — intervention group
Group type: COMPARATOR
Intervention: Oral DHA (120 mg; 422 micromol)
Number of subjects: 8
Study 12135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bioavailability of ARTS and DHA in ARTS perfusions
Number of subjects: 8
Study 12135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of ARTS (39 microM)
Number of subjects: 8
Study 12135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of DHA in ARTS perfusions (35 microM)
Number of subjects: 8
Study 12135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of DHA in DHA perfusions (35 microM)
Number of subjects: 8
Study 10463312 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study 10463312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse
Number of subjects: 12
Study 10463312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7593499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous albumin (20 g) administered immediately after oocyte retrieval
Number of subjects: 40
Study 2299810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprammonium (Cup) dialyzer
Number of subjects: 0
Study 2299810 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) dialyzer
Number of subjects: 0
Study 2299810 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant C5a
Number of subjects: 0
Study 6990675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg the night before and 400 mg on the morning of surgery
Number of subjects: 100
Study 6990675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31614277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 76
Study 31614277 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 76
Study 31614277 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS reward sensitivity
Number of subjects: 76
Study 31614277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of BD II
Number of subjects: 76
Study 31393651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-ceramic onlays (Lava Ultimate/3M)
Number of subjects: 120
Study 31393651 — intervention group
Group type: COMPARATOR
Intervention: Leucite‐reinforced ceramic onlays (IPS EmpressCAD)
Number of subjects: 120
Study 31393651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nano-ceramic and leucite-reinforced onlays
Number of subjects: 120
Study 30115552 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 77
Study 27699743 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam dressing
Number of subjects: 60
Study 27699743 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 60
Study 25047038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% SB705498 cream
Number of subjects: 16
Study 25047038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22232454 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 265
Study 22232454 — intervention group
Group type: COMPARATOR
Intervention: atovaquone-proguanil
Number of subjects: 265
Study 22232454 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 265
Study 21284248 — intervention group
Group type: EXPERIMENTAL
Intervention: New Pro‐Argin formula dentifrice containing 8.0% arginine, a high cleaning calcium carbonate system and 1450 ppm fluoride
Number of subjects: 122
Study 21284248 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously validated Pro‐Argin formula dentifrice containing 8.0% arginine, calcium carbonate and 1450 ppm fluoride
Number of subjects: 122
Study 21284248 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste containing calcium carbonate and 1450 ppm fluoride
Number of subjects: 122
Study 18691193 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 25
Study 18691193 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no Rx)
Number of subjects: 25
Study 16409095 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) used to evaluate AACD
Number of subjects: 20
Study 16409095 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 20
Study 16409095 — intervention group
Group type: COMPARATOR
Intervention: Control sites (not specified)
Number of subjects: 20
Study 12576261 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Number of subjects: 943
Study 12576261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study 10999870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg daily
Number of subjects: 122
Study 10999870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg daily
Number of subjects: 122
Study 10999870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 10999870 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening medication (all groups)
Number of subjects: 122
Study 10999870 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning medication (all groups)
Number of subjects: 122
Study 8997917 — intervention group
Group type: EXPERIMENTAL
Intervention: spouse‐assisted pain‐coping skills training
Number of subjects: 88
Study 8997917 — intervention group
Group type: EXPERIMENTAL
Intervention: CST (conventional CST intervention with no spouse involvement)
Number of subjects: 88
Study 8997917 — intervention group
Group type: COMPARATOR
Intervention: AE‐SS (arthritis education‐spousal support control condition)
Number of subjects: 88
Study 1467077 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 42
Study 1467077 — intervention group
Group type: EXPERIMENTAL
Intervention: No cricoid pressure
Number of subjects: 42
Study 6084452 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidolic oligomers (PCO) 300 mg/day for 5 days before and 5 days after surgery
Number of subjects: 32
Study 6084452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6084452 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidolic oligomers (PCO)
Number of subjects: 32
Study 31828172 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi pollen capsules (SPCs) for 7 weeks
Number of subjects: 288
Study 31828172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288